Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  European Heart Journal

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/EURHEARTJ/EHI312PMID 15888497
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death

  2012cited by this paper
• Cardiac arrest and sudden cardiac death

  2005cited by this paper
• Antibiotics; adverse effects: Oral erythromycin and the risk of sudden death from cardiac causes

  2004cited by this paper
• Genomics in sudden cardiac death.

  2004cited by this paper
• Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community.

  2004cited by this paper
• Implantable Defibrillators and Sudden Cardiac Death

  2004cited by this paper
• Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes

  2004cited by this paper
• Drug-induced prolongation of the QT interval.

  2004influential reference
• The incidence of sudden cardiac death in the general population.

  2004cited by this paper
• Mechanisms Underlying Conduction Slowing and Arrhythmogenesis in Nonischemic Dilated Cardiomyopathy

  2004cited by this paper
• Drug-induced prolongation of the QT interval.

  2004cited by this paper
• Antipsychotics and the risk of sudden cardiac death.

  2004cited by this paper
• QTc-prolonging drugs and hospitalizations for cardiac arrhythmias.

  2003cited by this paper
• Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

  2003cited by this paper
• Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management.

  2002cited by this paper
• Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.

  2002cited by this paper
• Task Force on Sudden Cardiac Death, European Society of Cardiology.

  2002cited by this paper
• Drug-Induced Long-QT Syndrome Associated With a Subclinical SCN5A Mutation

  2002cited by this paper
• Clinical and therapeutic aspects of congenital and acquired long QT syndrome.

  2002cited by this paper
• Antipsychotics and the risk of sudden cardiac death.

  2001cited by this paper
• Task Force on Sudden Cardiac Death of the European Society of Cardiology.

  2001cited by this paper
• QT Bumps: Unraveling the Mechanisms

  2001cited by this paper
• Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus

  2001cited by this paper
• Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders

  2000cited by this paper
• The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology.

  2000cited by this paper
• Pharmacogenetics of cardiac K(+) channels.

  2000cited by this paper
• Drug-induced proarrhythmic effects: assessment of changes in QT interval.

  2000cited by this paper
• [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension].

  2000cited by this paper
• Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.

  2000cited by this paper
• Postmarketing Surveillance Based on Electronic Patient Records: The IPCI Project

  1999cited by this paper
• The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada.

  1999cited by this paper
• 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

  1999cited by this paper
• Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes

  1998cited by this paper
• Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival.

  1997cited by this paper
• Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence.

  1996cited by this paper
• The Introduction of Computer-based Patient Records in the Netherlands

  1993cited by this paper
• 1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee.

  1993cited by this paper
• International primary care classifications: the effect of fifteen years of evolution.

  1992cited by this paper
• Modeling and variable selection in epidemiologic analysis.

  1989cited by this paper
• Epidemiology in Medicine

  1987cited by this paper
• Heart Disease: A Textbook of Cardiovascular Medicine

  1979cited by this paper

• Factors influencing QT interval prolongation during rifampicin-resistant tuberculosis treatment: a multicenter real-world study from China

  2025cites this paper
• Advanced Cardiovascular Toxicity Screening: Integrating Human iPSC-Derived Cardiomyocytes with 2D In Silico Models

  2025cites this paper
• Heart Rate-Corrected QT Interval Dynamics Following Antidepressant Switching from Escitalopram to High-Dose Venlafaxine: Cardiac Safety Insights from the Early Medication Change Cohort

  2025cites this paper
• Prescribing trends of fixed-dose combination of domperidone and proton-pump inhibitor across tertiary care centers in India, is the combination rational?

  2025cites this paper
• Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical analysis better?

  2025cites this paper
• A randomized controlled trial of the short-term effect of rosuvastatin on the corrected QT interval

  2025cites this paper
• Drug‐Induced QT Prolongation: Associations Between Risk Classifications in a Swedish Clinical Decision Support System and Clinical Outcomes

  2025cites this paper
• Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital

  2024cites this paper
• Associations of Clinical Characteristics With Sudden Cardiac Arrest in People With Type 2 Diabetes With and Without Cardiovascular Disease: A Longitudinal Case-Control Study Using Routine Primary Care Data.

  2024cites this paper
• Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study

  2024cites this paper
• A polygenic risk score for the QT interval is an independent predictor of drug-induced QT prolongation

  2024cites this paper
• Fluoroquinolones do not provide added risk of out-of-hospital cardiac arrest: a nationwide study

  2024cites this paper
• Effect on QTc interval by switching from methadone to equipotent R‐methadone dose in methadone maintenance treatment patients

  2024cites this paper
• Efficacy of omeprazole and domperidone fixed combination in the treatment of patients with functional dyspepsia: results from TANDEM study

  2023cites this paper
• Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study

  2023cites this paper
• Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study.

  2023cites this paper
• Pharmacological characterisation of electrocardiogram J-Tpeak interval in conscious Guinea pigs.

  2022cites this paper
• Cardiac safety and clinical efficacy of high-dose domperidone for long-term treatment of gastroparesis symptoms

  2022cites this paper
• Practical Approaches to Antipsychotic-Associated Corrected QT Interval Prolongation in Patients With Serious Mental Illness: A Review of Cases

  2022cites this paper
• Drug-induced Sudden Death: A Scoping Review

  2022cites this paper
• Use of Electrocardiogram Monitoring in Adult Patients Taking High-Risk QT Interval Prolonging Medicines in Clinical Practice: Systematic Review and Meta-analysis

  2022cites this paper
• Risk of out‐of‐hospital cardiac arrest in patients with epilepsy and users of antiepileptic drugs

  2022cites this paper
• Non-Cardiac Medications Induced QT Prolongation in Cardiac patients: A Retrospective Analysis

  2022cites this paper
• CHANGES IN THE QT INTERVAL IN PATIENTS WITH ANKYLOSING SPONDYLITIS

  2022cites this paper
• Acetylsalicylic acid use is associated with reduced risk of out-of-hospital cardiac arrest in the general population: Real-world data from a population-based study

  2022cites this paper
• Development in Prescriptions of Contraindicated and Potentially Harmful QT Interval–Prolonging Drugs in a Large Geriatric Inpatient Cohort From 2011 to 2021

  2022cites this paper
• Acquired long QT interval in athletes

  2022cites this paper
• Opioid use is associated with increased out‐of‐hospital cardiac arrest risk among 40 000‐cases across two countries

  2021cites this paper
• Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study

  2021cites this paper
• Genetic investigations of 100 inherited cardiac disease-related genes in deceased individuals with schizophrenia

  2021cites this paper
• Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

  2021cites this paper
• Off-label postpartum use of domperidone in Canada: a multidatabase cohort study

  2021cites this paper
• Non-cardiac depolarization-blocking drugs are associated with increased risk of out-of-hospital cardiac arrest in the community

  2021cites this paper
• Genetics and genomics of arrhythmic risk: current and future strategies to prevent sudden cardiac death

  2021cites this paper
• The role of QT-prolonging medications in a forensic autopsy study from Western Denmark.

  2021cites this paper
• Assessing Prescriber Behavior with a Clinical Decision Support Tool to Prevent Drug-Induced Long QT Syndrome

  2021cites this paper
• Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor

  2021cites this paper
• Domperidone Increases Harmful Cardiac Events in Parkinson's Disease: A Bayesian Re-Analysis of an Observational Study.

  2021cites this paper
• Out‐of‐hospital cardiac arrest and differential risk of cardiac and non‐cardiac QT‐prolonging drugs in 37 000 cases

  2021cites this paper
• Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis

  2021cites this paper
• A NOS1AP gene variant is associated with a paradoxical increase of the QT-interval shortening effect of digoxin

  2021cites this paper
• Use of ECG monitoring for adult patients taking high-risk QT interval-prolonging drugs in clinical practice: a systematic review protocol.

  2021cites this paper
• Multiple categories of non-cardiac QT-prolonging drugs are associated with increased risk of out-of-hospital cardiac arrest: real-world data from a population-based study

  2021influential citation
• The CredibleMeds® list: Usage of QT interval prolonging drugs in Germany and discordances with prescribing information

  2021cites this paper
• Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta‐analysis of observational studies

  2021cites this paper
• Drug-induced long qt syndrome

  2020cites this paper
• Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects

  2020cites this paper
• Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death.

  2020cites this paper
• CME-EKG 66: Torsade de pointes: die Gefahr der rotierenden Herzachse

  2020cites this paper
• Top 20 drug − drug interactions, polypharmacy and analysis of the nature of risk factors due to QT interval prolonging drug use in elderly psychiatry outpatients

  2020cites this paper
• [CME ECC 66: Torsade de Pointes: The Danger of a Rotating Heart Axis].

  2020cites this paper
• Clinically significant incidental QTc prolongation is subject to within‐individual variability

  2020cites this paper
• Effects of Anisodine Hydrobromide on the Cardiovascular and Respiratory Functions in Conscious Dogs

  2020cites this paper
• Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system

  2020cites this paper
• Should we still monitor QTc duration in frail older patients on low-dose haloperidol? A prospective observational cohort study.

  2020cites this paper
• Comparison of two algorithms to support medication surveillance for drug-drug interactions between QTc-prolonging drugs

  2020cites this paper
• Risk of domperidone induced severe ventricular arrhythmia

  2020cites this paper
• Cardiac Arrhythmias

  2020cites this paper
• Shock From Twisting Peaks: A Rare Case of Recurrent Torsades de Pointes Secondary to Leuprolide-Induced Prolonged QT

  2020cites this paper
• Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End‐Stage Kidney Disease

  2020cites this paper
• From domperidone to metopimazine: Anticipating the media impact of pharmacovigilance announcements.

  2020cites this paper
• Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.

  2019cites this paper
• CARDIAC TOXICITY OF FLUOROQUINOLONES AND BEDAQUILINE

  2019cites this paper
• Evaluating the Effect of a 14-Day Course of Domperidone on Breast Milk Production: A Per-Protocol Analysis from the EMPOWER Trial

  2019cites this paper
• Full title: Managing cardiovascular risk of macrolides: systematic review and meta- analysis Running title: Managing cardiovascular risk of macrolides

  2019cites this paper
• Кардиотоксические свойства фторхинолонов и бедаквилина

  2019cites this paper
• Sudden Unexpected Death and the Mammalian Dive Response: Catastrophic Failure of a Complex Tightly Coupled System

  2019cites this paper
• The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors

  2019cites this paper
• Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries

  2019cites this paper
• Proarrhythmic Effect of Acetylcholine-Esterase Inhibitors Used in the Treatment of Alzheimer’s Disease: Benefit of Rivastigmine in an Experimental Whole-Heart Model

  2019cites this paper
• Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe

  2019cites this paper
• Number of ECG Replicates and QT Correction Formula Influences the Estimated QT Prolonging Effect of a Drug

  2019cites this paper
• Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs

  2019cites this paper
• Cardiovascular safety of prokinetic agents: A focus on drug‐induced arrhythmias

  2018cites this paper
• Fatal Drowning Associated with QT Prolongation Caused by Alcohol, Some Drugs, and Congenital Long QT Syndrome: The Role of the Diving Reflex

  2018cites this paper
• A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide

  2018cites this paper
• Increased risk of all‐cause mortality associated with domperidone use in Parkinson's patients: a population‐based cohort study in the UK

  2018cites this paper
• QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors

  2018cites this paper
• Association between QTc prolongation and mortality in patients with suspected poisoning in the emergency department: a transnational propensity score matched cohort study

  2018cites this paper
• Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides

  2018cites this paper
• Risk for cardiovascular disease in patients with nontuberculous mycobacteria treated with macrolide.

  2018cites this paper
• Predictors of mortality in high-risk patients with QT prolongation in a community hospital.

  2018cites this paper
• Prevalence and Outcome of High-Risk QT Prolongation Recorded in the Emergency Department from an Institution-Wide QT Alert System.

  2018cites this paper
• Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort

  2017cites this paper
• Diese kardialen Komplikationen drohen nach Schlaganfall

  2017cites this paper
• Contribution of medications and risk factors to QTc interval lengthening in the atherosclerosis risk in communities (ARIC) study

  2017cites this paper
• Effect of Long-term, Low-Dose Erythromycin on Pulmonary Exacerbations Among Patients With Non-Cystic Fibrosis Bronchiectasis

  2017cites this paper
• Role of risk stratification and genetics in sudden cardiac death.

  2017cites this paper
• [Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance database].

  2017cites this paper
• Media attention regarding sudden cardiac death associated with domperidone use does not affect in hospital ECG recording

  2017cites this paper
• Risk factors for QTc interval prolongation

  2017cites this paper
• Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports

  2017cites this paper
• Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study

  2017cites this paper
• Torsades de Pointes after Ondansetron Infusion in 2 Patients.

  2017cites this paper
• Domperidone is Commonly Prescribed With QT-Interacting Drugs: Review of a Community-based Practice and a Postmarketing Adverse Drug Event Reporting Database

  2017cites this paper
• Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience

  2017cites this paper
• Domperidone: The Forbidden Fruit

  2017cites this paper
• Global Optimization of Ventricular Myocyte Model to Multi-Variable Objective Improves Predictions of Drug-Induced Torsades de Pointes

  2017cites this paper
• Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis

  2017cites this paper
• Should Domperidone be Used as a Galactagogue? Possible Safety Implications for Mother and Child

  2017cites this paper